FcRn blocker (investigational)

Imeroprubart

An investigational treatment for Myasthenia Gravis.

Phase 3by Immunovant (majority owned by Roivant)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Imeroprubart wherever you encounter it, plus the key facts at a glance.

Generic name: Imeroprubart
Development code: IMVT-1402
Drug class: FcRn blocker (investigational)
Manufacturer: Immunovant (majority owned by Roivant)
How it's taken: Injection under the skin once a week (in trials)

An investigational antibody injected under the skin once a week in trials. It blocks FcRn so the body clears IgG antibodies, including the autoantibodies behind generalized myasthenia gravis, faster. Immunovant expects topline data from its Phase 3 myasthenia gravis trial in 2027.

Follow Imeroprubart by email

We'll email you when the FDA acts on Imeroprubart and when new trials for Myasthenia Gravis open. Unsubscribe anytime.

You'll get, for Myasthenia Gravis:

Trial Alerts, when a new trial opens or a trial changes
Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month

Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

How Imeroprubart works

FcRn is a receptor that recycles IgG antibodies so they stay in the blood longer. IMVT-1402 is a fully human monoclonal antibody that blocks FcRn, so IgG antibodies, including the autoantibodies that drive myasthenia gravis, are cleared faster^[1]. The approved myasthenia gravis medicines Vyvgart (efgartigimod), Rystiggo (rozanolixizumab) and Imaavy (nipocalimab) also block FcRn. No trial has compared IMVT-1402 with any of them.

Clinical trial results

The Phase 3 myasthenia gravis trial (NCT07039916) plans to enroll 231 adults with mild to severe generalized myasthenia gravis and compares 2 weekly doses with placebo. Its main measure is the change in the MG-ADL daily-living score at week 12 in antibody-positive patients, and its primary completion date is listed as December 2027^[5].

Graves' disease trials NCT06727604 (240 adults) and NCT07018323 (210 adults) measure how many people have normal thyroid levels without antithyroid drugs at week 26^[6]^[7]. A CIDP trial (NCT07032662, 162 adults) measures how many stay relapse-free at week 24^[8], and a Sjögren's disease trial (NCT06979531, 180 adults) has finished enrolling. Immunovant expects topline myasthenia gravis and Graves' data in 2027 and CIDP and Sjögren's data in 2028^[3].

Side effects and safety

Early trial safety observations

No side effect results for IMVT-1402 from its myasthenia gravis, Graves' disease or CIDP trials had been published as of November 2026; Immunovant expects topline data from them in 2027 and 2028^[3].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Imeroprubart

In trials, IMVT-1402 is given as an injection under the skin once a week. The myasthenia gravis trial tests 2 doses against placebo for 12 weeks, followed by longer treatment with IMVT-1402 for every group^[5].

Development history

IMVT-1402 is Immunovant's second FcRn antibody. Its first, batoclimab, missed its main goal in 2 Phase 3 thyroid eye disease trials reported on April 2, 2026, and Immunovant is winding down the batoclimab trials while it focuses on IMVT-1402^[4]^[3]. Immunovant now also uses the official name imeroprubart^[2].

Ask anything about Imeroprubart

AI-powered answers from clinical trial databases, FDA reports, and medical literature

Start withor ask

Explore Myasthenia Gravis trials

Other Myasthenia Gravis treatments

Common questions about Imeroprubart

▸What is Imeroprubart?

▸How does Imeroprubart work?

▸What are the side effects of Imeroprubart?

No side effect results for IMVT-1402 from its myasthenia gravis, Graves' disease or CIDP trials had been published as of November 2026; Immunovant expects topline data from them in 2027 and 2028^[3].

▸How is Imeroprubart taken?

▸Is Imeroprubart FDA approved?

Imeroprubart is currently in phase 3 clinical trials for Myasthenia Gravis. It has not yet received FDA approval.

▸When could IMVT-1402 be approved for myasthenia gravis?

No approval date exists yet. Immunovant expects topline results from its Phase 3 myasthenia gravis trial in 2027 and has not announced when it would file with the FDA^[3].

Trial: NCT07039916, recruiting adults with generalized myasthenia gravis.

FcRn blockers already approved for myasthenia gravis: Vyvgart (efgartigimod), Rystiggo (rozanolixizumab) and Imaavy (nipocalimab).

Source: Immunovant, August 6, 2026, and ClinicalTrials.gov.

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

Immunovant. Immunovant pipeline: IMVT-1402. https://www.immunovant.com/pipeline
Immunovant. About Immunovant. https://www.immunovant.com/about-us
Immunovant · 2026-08-06. Immunovant provides corporate updates and reports financial results for the quarter ended June 30, 2026. https://www.immunovant.com/investors/news-events/press-releases/detail/85/immunovant-provides-corporate-updates-and-reports-financial
Immunovant · 2026-04-02. Immunovant announces Phase 3 study results for batoclimab in thyroid eye disease. https://www.immunovant.com/investors/news-events/press-releases/detail/81/immunovant-announces-phase-3-study-results-for-batoclimab
ClinicalTrials.gov. IMVT-1402 in generalized myasthenia gravis. https://clinicaltrials.gov/study/NCT07039916
ClinicalTrials.gov. IMVT-1402 in Graves' disease. https://clinicaltrials.gov/study/NCT06727604
ClinicalTrials.gov. IMVT-1402 in Graves' disease. https://clinicaltrials.gov/study/NCT07018323
ClinicalTrials.gov. Imeroprubart in CIDP. https://clinicaltrials.gov/study/NCT07032662